DNB Carnegie acted as sole bookrunner in the directed share issue of 11.5 million shares at a subscription price of SEK 13.75 per share.
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs.